Nadia Arcon
B, Argentina
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
The Immune-Stimulating Particle Adjuvant (ISPA) as a Versatile Adjuvant Platform for Recombinant Vaccines Against Chronic Toxoplasma gondii Infection.
Journal: Acta tropica
Published: February 09, 2026
The immune-stimulating particle adjuvant (ISPA) as a versatile adjuvant platform for recombinant vaccines against chronic Toxoplasma gondii infection.
Journal: Acta tropica
Published: February 09, 2026
Maternal stress increases risk of allergic lung inflammation in adult mice.
Journal: Immunobiology
Published: February 12, 2023
Contribution of Kazal-Like Domains of the Serine Protease Inhibitor-1 from Toxoplasma gondii in Asthma Therapeutic Vaccination Effectiveness.
Journal: International archives of allergy and immunology
Published: April 26, 2021
Chronic infection with the protozoan Toxoplasma gondii prevents the development of experimental atopic dermatitis in mice.
Journal: Journal of dermatological science
Published: June 14, 2019
Vaccine potential of antigen cocktails composed of recombinant Toxoplasma gondii TgPI-1, ROP2 and GRA4 proteins against chronic toxoplasmosis in C3H mice.
Journal: Experimental parasitology
Published: May 29, 2017
Toxoplasma gondii serine-protease inhibitor-1: A new adjuvant candidate for asthma therapy.
Journal: PloS one
Published: February 21, 2017
Homologous prime-boost strategy with TgPI-1 improves the immune response and protects highly susceptible mice against chronic Toxoplasma gondii infection.
Journal: Acta tropica
Published: January 19, 2015
Showing 1-9 of 9
Last Updated: 09/26/2026